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Abstract
Introduction: The aim of the study was to demonstrate Interleukin-18 (IL-18) expression
in keratinocytes from psoriatic lesions in comparison to keratinocytes from uninvolved
skin and to study the change of expression after therapeutic interventions.
Material and methods: This study included 16 patients of different clinical
subtypes of psoriasis. IL-18 gene expression analysis was performed using real-
time quantitative PCR. Three biopsies were obtained from each patient. Two
were taken from the lesional psoriatic skin and from uninvolved skin before
starting treatment. A third lesional skin biopsy was taken at the end of two
months' treatment course. The treatment was in the form of topical steroids or
oral systemic methotrexate. 
Results: Of all 16 studied patients significantly increased IL-18 expression was
noted in keratinocytes from psoriatic lesions before and after treatment when
compared to keratinocytes from uninvolved skin (P = 0.001 and 0.002
respectively). The IL-18 expression in the skin lesions after treatment was
significantly lower than lesional skin before treatment (P = 0.023). In psoriatic
skin lesions of all studied patients IL-18 expression was significantly correlated
with disease duration (r = 0.40 and P = 0.01) and clinical severity of psoriasis
(r = 0.72 and P = 0.001). 
Conclusions: Increased IL-18 expression in keratinocytes from psoriatic lesions
of our patients and its correlation with disease duration and severity supported
the concept which views psoriasis as a T-cell-mediated autoimmune disease.
This could establish therapeutic and preventive approaches for psoriasis that
ultimately lead to improved outcomes for patients. 
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Introduction
Psoriasis is a chronic inflammatory condition which is the result of
persistent stimulation of T cells by antigens of epidermal origin [1]. This
persistent stimulation of T cells is the result of an interaction between T cells,
antigen-presenting cells, i.e. Langerhans cells, and antigens, and comprises
the following steps: primary signals (signal 1) including T-cell receptor
stimulation by peptide antigen, co-stimulation (so-called accessory signals)
(signal 2), and T helper type 1 (Th 1) differentiation and proliferation [2].
In 1986, it was proposed that cytokines released by activated 
T-lymphocytes initiate and maintain the psoriatic process by stimulating
keratinocyte proliferation [3]. Since that time it has become clear that,
upon stimulation, keratinocytes are also able to secrete an array of different
cytokines with a variety of functional effects on both themselves and other
cell types, including T-lymphocytes [4].
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Copyright © 2010 Termedia & BanachInterleukin-18 (IL-18) is related to the IL-1 family
in terms of both structure and function. At the
receptor level, the activity of IL-18 takes place
through a signalling chain of a putative IL-18
receptor (IL-18R) complex [5].
Interleukin-18 was first described as an
interferon-γ (IFN-γ) inducing factor. In general, IL-18
induction of IFN-γ is similar to that of IL-12, when
it is a sole cytokine. IL-18 induces low levels of IFN-
γ, but in the presence of co-stimulants, IFN-γ
production is greatly enhanced [6]. However,
because antibodies to IL-18 also reduced the
hepatotoxicity of endotoxaemia, IL-18 was
considered to possess other biological properties
beyond that of inducing IFN-γ [7]. IL-18 activates T
cells to synthesize IL-2, GM-CSF, and TNF-α. There
are also reports that IL-18 suppresses the production
of IL-10 and does not induce the production of IL-
1Ra. In general, the ability of IL-18 to induce different
cytokines depends on the cellular targets [8]. Flisiak
et al. confirmed an association between plasma IL-
18 concentration and psoriasis severity. Moreover,
it was shown that combined measurement of IL-18
and TGF-beta1 in plasma can be considered as
a possible biomarker of psoriasis activity [9]. 
Kato  et al. indicated that a single nucleotide
polymorphism (SNP) in the promoter of the
interleukin-18 gene is associated with the presence
of psoriasis, but not atopic dermatitis. This suggests
that the SNP is associated with susceptibility to
psoriasis vulgaris, presumably by affecting the
production of IL-18 [10].
A few studies have analysed IL-18 expression in
psoriasis vulgaris [11-14]. Much less information is
available on the ability of different therapeutic
interventions to modulate ongoing changes in
expression in chronic disorders, especially in
a human disease like psoriasis. 
The aim of this study was to demonstrate
expression of IL-18 in keratinocytes from psoriatic
lesions in comparison to keratinocytes from non-
lesional skin and to study the change of IL-18
expression after therapeutic interventions. 
Material and methods
This study included 16 patients. The patients
were selected from the outpatient clinic of Benha
University Hospital, Al-Haud Al-Marsoud and The
National Research Center, Cairo, Egypt. The patients
included 4 (25%) females and 12 (75%) males, and
their ages ranged from 21 to 62 years with a mean
of 40.87 ±13.17 years. They had different clinical
subtypes of psoriasis and exhibited various degrees
of severity. History of present illness included the
onset, course, duration, previous treatment and
date of last topical application or systemic therapy.
Inclusion criteria: those included in the study were
adult psoriatic patients ≥ 18 years who should not
have received a topical therapeutic modality apart
from petrolatum for the last four weeks or systemic
therapy for the last eight weeks. 
Presence or absence of any coexisting non-
cutaneous conditions was established. Three
patients were hypertensive, three had psoriatic
arthropathy, one had hepatitis C virus (HCV) with
anaemia of chronic disorder type and one had
diabetes mellitus with hypertension. A positive
family history was encountered only in one case.
Two patients had upper respiratory tract infections;
cold exposure worsened five patients' clinical
presentation; sweating aggravated one patient's
condition; three patients had psychogenic factors
precipitating their cases. Only five of the studied
patients were not affected by predisposing factors
(31.3%). 
The psoriasis area and severity index (PASI) score
sheet was adopted according to Fredriksson and
Pettersson and Marks et al. [15, 16] for all patients
as an indication of degree of severity. In mild cases,
the extent of the disease does not exceed 10, while
in severe cases, the extent of the disease is more
than 30 based on the PASI score [17]. Informed
consent was obtained after complete description
of the study from each participant, according to the
guidelines of the local ethical committee of the
National Research Center.
Two biopsies were taken from each patient in
the first set. The first biopsy was taken from the
lesional psoriatic skin and the second from non-
lesional skin. All patients were subjected to
continuous treatment (in the form of topical
steroids and oral systemic methotrexate) and
followed up for 2 months. Six patients with
moderate to severe degrees of psoriasis and two
with palmoplantar subtype of psoriasis (who did
not respond to topical steroids) received oral
systemic methotrexate. The dosage used was:
15 mg per week in three divided doses taken at 
12-hour intervals during a 24-hour period with folate
supplementation. Patients receiving systemic
methotrexate were subjected to monitoring liver
blood tests monthly. Eight patients with mild to
moderate degrees of psoriasis were maintained on
topical steroid creams and ointments in the form
of betamethasone dipropionate, twice daily. At the
end of the course of two months, a third psoriatic
lesional skin biopsy was taken from all patients. 
Tissue processing and preparation
To prevent degradation by intracellular RNases,
tissues were embedded soon after excision in RNA
stabilizing reagent RNAlater provided from QIAGEN
worldwide companies according to the ma  -
nufacturer's instructions to be stored at –70°C
before sample processing. Frozen tissues were not
allowed to thaw during handling to be ready for
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was weighed before processing. Biopsies weighed
up to 20 mg. Efficient disruption and homo  -
genization of the starting material was performed
using a rotor-stator homogenizer.
RNA extraction and complementary (c) 
DNA synthesis
Total RNA was extracted using QIA amp RNA
extraction kit provided from QIAGEN worldwide
companies. The concentration and purity of RNA
were determined by measuring its absorbance at
260 nm (A260) and 280 nm (A280) in a UV visible
spectrophotometer. Total RNA (2 μg) was reverse-
transcribed to cDNA with High-Capacity cDNA
Archive kit provided from Applied Biosystems.
cDNAs were stored at –20°C until real-time
quantitative PCR was performed. 
Gene expression quantitation
Real-time quantitative PCR was performed using
Applied Biosystems Perkin Elmer 7300 sequence
detection system. Primers were IL-18 sense primer
5'-AGG AAT AAA GAT GGC TGC TGA AC-3' and anti-
sense primer 5'-GCT CAC CAC AAC CTC TAC CTC C-
3'. Each PCR reaction (in a 50 uL volume) contained
1 x of TaqMan universal PCR master mix, (2 x) 50
to 900 nM of forward primer, 50 to 900 nM of
reverse primer, 250 nM of TaqMan probe labelled
with 6-carboxyfluorescein (FAM) and 10 to 100 ng
of cDNA. The amplification protocol was 2 min at
50°C, 10 min at 95°C, then 40 cycles for 15 sec at
95°C and 1 min at 60°C. Relative gene expression
was determined for each sample. Amplification of
the gene for glyceraldehydes-3-phosphate dehydro  -
genase (GAPDH), a constitutively expressed
housekeeping gene, was performed on all samples.
All genes were subsequently normalized against
GAPDH levels. In this study mRNA levels were
expressed in picograms/microlitre (pg/μl).
Statistical analysis
All data were collected from the patient charts
and entered into a computerized spreadsheet. The
fit of the data to the normal distribution was tested
with the Kolmogorov-Smirnov test. Since the
distribution of the data was significantly different
from normal, nonparametric statistics were further
used. Comparisons were made using Mann-
Whitney U, Kruskal Wallis and Wilcoxon signed
ranks tests between variables adjusted for
appropriate covariates, and Spearman rank
correlation coefficients were calculated between
the assessed variables. The null hypothesis was
rejected with a two-sided P value of < 0.05. All
analyses were performed with SPSS 11.0 for
Macintosh (Statistical Package for the Social
Sciences. SPSS Inc., Chicago, IL, U.S.A.).
Results
Demographic and behavioural characteristics of
included patients are presented in Table I. PASI
score used to evaluate the severity of psoriasis
varied from 1.4 to 39 with a mean of 14.96 ±11.82.
According to Ramsay and Lawrence [17], the PASI
score grades in the different subtypes of psoriasis
are demonstrated in Table II. 
Results of quantitative PCR
All patients had detectable levels of IL-18 mRNA
in the uninvolved skin. Table 3 shows the range,
mean ± SD and median levels of cytokine gene
expression in each skin biopsy at the different times
before and after receiving medication whether
topical or systemic. Comparisons between median
IL-18 expression levels with percentiles in all studied
patients are presented in Figure 1.
Characteristics Patients
Age range (mean ± SD) [years] 21-62 (40.875 ±13.17)
Sex (M/F ) 12/4
Marietal status (+/–) 13/3
Occupation (working/notworking) 12/4
Smoking (+/–) 4/12
Duration of disease range  2 months - 14 years
(mean ± SD) in years 5.88 ±4.50
Family history (+/–) 1/15
Provoking factors (+/–) 11/5
Associated diseases (+/–) 8/8
Table I. Demographic and behavioural characteristics
of patients with psoriasis
Type of psoriasis  PASI score grades
Mild* Moderate*S evere*T otal (%)
Plaque-type 3 2 1 6 (37.5)
Erythrodermic 1 1 (6.3)
Guttate 1 1 (6.3)
Flexural 1 1 (6.3)
Palmoplantar 2 2 (12.5) 
Plaque and gutt  2 2 (12.5)
Plaque and p.p  1 1 (6.3)
Plaque and flex  1 1 (6.3)
Plaque and nails 1 1 (6.3)
Total 7 7 2 16
Table II. The range of the PASI score in the different
types of psoriasis
gutt – guttate, p.p – plamoplantar, flex – flexural 
*According to Ramsay and Lawrence [17]:
Mild cases – the PASI score did not exceed 10
Moderate cases – the PASI score was > 10 to 30
Severe cases – the PASI score was more than 30
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skin than lesional skin before treatment (P = 0.001)
and lesional skin after treatment (P = 0.002) was
observed in all studied patients as one group. The
IL-18 expression in the psoriatic skin lesions after
treatment was significantly lower than lesional skin
before treatment (P = 0.023).
IL-18 mean expression levels in non-lesional and
lesional skin (before and after treatment) in the
different subtypes of psoriasis are shown in Figure 2.
The highest expression level was noted in plaque
and nails clinical subtype of psoriasis.
Among patients receiving topical steroids
significantly lower IL-18 expression was detected
in non-lesional skin than lesional skin before
treatment (P = 0.012) and after treatment 
(P = 0.012). No statistical significance was obtained
when comparing the change of expression before
and after topical treatment (P = 0.069). 
Individual variations of the IL-18 expression
levels in non-lesional and lesional skin before and
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Figure  1. Comparisons between median IL-18
expression levels with percentiles in all studied
patients. Significantly lower IL-18 expression in
uninvolved skin than  lesional skin before treatment
(P = 0.001) and lesional skin after  treatment 
(P = 0.002) was demonstrated in all studied patients
as one group. The IL-18 expression  in the psoriatic
skin lesions after treatment was significantly lower
than lesional skin before treatment (P = 0.023)
7
6
5
4
3
2
1
0
IL-18 non lesional      IL-18 before treatment      IL-18 after treatment
Figure 2. IL-18 expression levels in non lesional and
lesional skin (before and after treatment) in the
different subtypes of psoriasis. The highest
expression level was noted in plaque and nails
clinical subtype of psoriasis
Variant N Mean ± SD Range Percentiles
25th 50th (mMedian)7 5 th
All studied patients
IL-18 NL 16 1.10 ±2.14 0.01-7.90 0.0300 0.1850a 1.2675
IL-18 LB 16 3.24 ±5.63 0.17-22.70 0.4900 0.9050 4.9000
IL-18 LA 16 1.78 ±2.72 0.01-8.10 0.2750 0.4600b 1.5250
Patients on TS
IL-18 NL 8 0.26 ±0.44 0.01-1.3 0.014 0.051c 0.337
IL-18 LB 8 1.59 ±2.1 0.17-6.4 0.2275 0.53 2.53
IL-18 LA 8 0.61 ±.58 0.012-1.6 0.1275 0.415 1.2
Patients on MTX
IL-18 NL 8 1.93 ±2.84 0.012-7.9 0.1625 0.685d 3.775
IL-18 LB 8 4.89 ±7.56 0.49-22.7 0.602 1.385 6.2
IL-18 LA 8 2.95 ±3.52 0.26-8.10 0.3275 0.745 7.26
Table III. IL-18 expression levels in psoriatic patients
IL-18 NL – IL-18 in non-lesional skin, IL-18 LB – IL-18 in lesional skin before treatment, IL-18 LA – IL-18 in lesional skin after treatment, TS – topical
steroids, MTX – methotrexate
aSignificantly lower than lesional skin before treatment (P = 0.001) and lesional skin after treatment (P = 0.002)
bSignificantly lower than lesional skin before treatment (P = 0.023)
cSignificantly lower than lesional skin before treatment (P = 0.012) and after treatment (P = 0.012)
dSignificantly lower than lesional skin before treatment (P = 0.018) 
Plaque type
Erythrodermic
Guttate
Flexural
Palmoplantar
Plaque & Guttate
Plaque & Palmoplanter
Plaque & Flexural
Plaque & Nails
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Figure  3.  The individual variations of the IL-18
expression levels in non lesional and lesional skin
before and after receiving topical steroids .
Significantly lower IL-18 expression was detected in
non lesional skin than lesional skin before treatment
(P = 0.012) and after treatment (P = 0.012). No
statistical significance could be obtained when
comparing the change of expression before and after
topical treatment (P = 0.069) 
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Figure  4.  The individual variations of the IL-18
expression levels in non lesional and lesional skin
before and after receiving systemic methotrexate.
significantly lower IL-18 expression was detected in
non lesional skin than lesional skin before treatment
(P = 0.018). The change of expression levels in lesional
skin after treatment was not statistically significant
when compared to non lesional skin (P = 0.069) and
lesional skin before treatment (P = 0.12)
after receiving topical steroids are presented in
Figure 3. 
In patients receiving methotrexate, signi  -
ficantly lower IL-18 expression was detected in
non-lesional skin than lesional skin before
treatment (P = 0.018). The change of expression
levels in lesional skin after treatment was not
statistically significant when compared to non-
lesional skin (P = 0.069) and lesional skin before
treatment (P = 0.12).
Individual variations of the IL-18 expression levels
in non-lesional and lesional skin before and after
receiving systemic methotrexate are shown in
Figure 4. 
In the correlation between IL-18 expression and
different demographic and behavioural charac  -
teristics of the studied patients as one group,
a significant correlation was obtained between 
IL-18 expression levels in psoriatic lesions and 
the severity of psoriasis expressed by PASI 
score (r = 0.72 and P = 0.001) and disease duration
(r = 0.40 and P = 0.01). No significant correlation
was revealed between IL-18 expression levels in
psoriatic lesions and patients’ age, smoking status,
predisposing factors or coexisting diseases.
Discussion
In the present study our patients with psoriasis
showed significantly increased IL-18 expression in
keratinocytes from psoriatic lesions before and after
receiving medication whether topical or systemic
in comparison to keratinocytes from non-lesional
skin. This supports the concept viewing psoriasis
as a T-cell-mediated autoimmune disease. Krueger
[18] reported, in his study on a large series of skin
biopsies, increased protein expression in lesional
as opposed to non-lesional skin samples. Other
investigators stated that lesional skin might be the
source of the elevated plasma levels of IL-18 [19].
In the present work quantitative PCR using mRNA
taken from uninvolved skin revealed low but
detectable levels of IL-18 mRNA expression. This
finding is consistent with previous studies showing
that human keratinocytes are capable of
synthesizing low levels of IL-18 mRNA even under
non-stimulated conditions [20]. Chang et al. [21]
found that genes specifically modulated in
uninvolved skin play a major role in triggering
disease progression, and in being the first candidate
for early disease diagnosis or development of new
therapies. This finding could allow selection of the
treatment regimen for individual patients. 
In the present study the IL-18 expression in
patients receiving topical steroids was significantly
lower in non-lesional skin than lesional skin before
and after treatment. After 2 months of treatment,
IL-18 expression levels returned back to low values
but not significantly lower than the lesional skin
levels of expression before treatment. In patients
receiving methotrexate non-lesional skin expression
was significantly lower than lesional skin before
treatment. Also the expression levels decreased
after treatment but still not statistically significantly
when compared to lesional skin before treatment.
Otkjaer et al. [22] determined IL-19 and IL-20 in non-
lesional and lesional psoriatic skin after 28 days of
treatment using topical calcipotriol ointment for
mild cases and oral cyclosporine for moderate and
severe cases. They found that in patients treated
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levels in lesional psoriatic skin were reduced after
14 days, but the reduction became statistically
significant only after 28 days. So the timing for
mRNA expression analysis could affect the degree
of significance. This is further supported by studies
demonstrating a decrease of IL-18 levels after
narrowband UVB therapy together with other
parameters' characteristics for the T helper 1 (Th1)
response [23]. Apart from stimulating the Th1
response, IL-18 can regulate the Th2 response
depending on the local cytokine network. IL-12
enhances IFN-γ production induced by IL-18,
whereas IL-18 alone induces IL-4 and IL-13
production [24].
Classic systemic treatments for psoriasis have
not fully met the needs of patients for permanent
improvement. Antibody-based or fusion protein–
based selective targeting of key mediators of
inflammation has been added to the treatment
approaches for psoriasis. Kong et al., and Smeltz
[25, 26] studied IL-18 receptor blocking by using
1,25-dihydroxyvitamin D in mouse keratinocytes.
They observed that the IL-18 expression level was
decreased synchronously with treatment. Tak et al.
[27] investigated IL-18 binding protein (IL-18 BP) in
psoriatic patients and demonstrated that IL-18 BP
neutralizes the activity of IL-18. 
Our study demonstrated that IL-18 expression in
the psoriatic lesions before treatment was
significantly correlated with the severity of psoriasis
and disease duration. No correlation was noted
between IL-18 expression and patients’ age,
smoking status, predisposing factors or coexisting
diseases. Flisiak et al. [9] found a significant
correlation between plasma IL-18 levels and PASI
values. But they did not find any correlation
between IL-18 concentration in scales and PASI
score. Trinquet et al. [28] studied the influence of
disease duration on gene expression profiles in
psoriasis. They did not reveal any correlation.
However, Craven et al. [29] studied IL-10 in early and
late onset psoriasis and confirmed that IL-10
expression was correlated significantly with disease
duration. Sampogna et al. [30] studied 380 patients
with psoriasis and did not find any significant
difference between older and younger patients
regarding IL-18 levels. On the other hand, Chen et
al. [31] found a statistically significant correlation
between IL-18 expression levels and age, with 
a P value of 0.015. 
In conclusion, based on the increased IL-18
expression levels in psoriatic skin lesions relative
to uninvolved skin, this cytokine appears to be
crucial in the development of the active psoriatic
lesion itself, where it is produced locally by a step
in the evolution of the psoriatic lesion. This could
be supported by its correlation with clinical severity
and disease duration, and reduction of its
expression after treatment. The decreased
expression after treatment was not to an extent
indicating that the skin had returned to normal. The
small size of the study population and the
heterogeneous group of patients participating in
the study preclude the drawing of firm conclusions.
Future studies on genes involved and array-based
technologies should allow confirmation of the results
obtained. Also further studies are recommended to
try other lines of treatment for psoriasis. One of
these lines of therapy is to try r-h IL-18 BP to
neutralize IL-18 activity on a wide scale that will
ultimately lead to improved outcomes for patients. 
References
1. Homey B, Dieu-Nosjean, MC, Wiesenborn A, et al. Up-
regulation of macrophage inflammatory protein-3
alpha/CCL20 and CC chemokine receptor 6 in psoriasis. 
J Immunol 2000; 164: 6621-32.
2. Krueger JG. The immunologic basis for the treatment of
psoriasis with new biologic agents. J Am Acad Dermatol
2002; 46: 1-23.
3. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis:
a disease of abnormal keratinocyte proliferation induced
by T-lymphocytes. Immunol Today 1986; 7: 256-9.
4.  Barker BS, Fry L. The immunology of psoriasis. Br 
J Dermatol 1992; 126: 1-9.
5. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M,
Kunikate T. Purification and characterization of the human
interleukin-18 receptors. J Biol Chem 1997; 272: 25737-42.
6.  Mastroeni P . Immunity to systemic salmonella infections.
Curr Mol Med 2002; 2: 393-406. 
7. Dinarello CA. Novel target for interleukin-18 binding
protein. Ann Rheum Dis 2001; 60: 18-24.
8.  Wigginton JM, Wiltrout RH. IL-12, IL-2 combination
cytokine therapy for solid tumours: translation from
bench to beside. Expert. Opin Biol Ther 2002; 2: 513-24.
9. Flisiak I, Klepacki A, Chodynicka B. Plasma and scales
levels of interleukin 18 in comparison with other possible
clinical and laboratory biomarkers of psoriasis activity.
Biomarkers 2006; 11: 194-200.
10. Kato T, Tsunemi Y, Saeki H, et al. Interferon-18 gene
polymorphism -137 G/C is associated with susceptibility
to psoriasis vulgaris but not with atopic dermatitis in
Japanese patients. J Dermatol Sci 2009; 53: 162-3. 
11. McKenzie RC, Boyce F, Forsey R, et al. Psoriatic skin
expresses high levels of interleukin-18 (IL-18) and IL-18
receptor (IL-18R). Br J Dermatol 2000; 142: 618.
12. Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in
psoriasis. Arch Dermatol Res 2001; 293: 334-42.
13. McKenzie RC, Boyce F, Szepietowski JC, et al. Psoriatic
epidermis expresses high levels of interleukin 18 (IL-18),
IL-18 receptor mRNA and IL-18. Dermatol Klin 2002; 1-4:
17-23.
14. McKenzie RC, Sabin E, Szepietowski JC, Gracie JA, Forsy
RJ, Howie S. Interferon gamma in keratinocytes in
psoriasis. Eur J Dermatol 2003; 13: 315-6. 
15. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy
with a new retinoid. Dermatologica 1978; 157: 238-44.
16. Marks R, Barton S, Shuttelworth D, Finlay AY. Assessment
of disease progress in psoriasis. Arch Dermatol 1989; 125:
235-40.
17. Ramsay B, Lawrence CM. Measurement of involved
surface area in patients with psoriasis. Br J Dermatol 1991;
124: 565-70.
Interleukin-18 expression and the response to treatment in patients with psoriasis
Arch Med Sci 6, December / 2010 96918. Krueger J. What clinical trials teach us about the biology
of psoriasis? Br J Dermatol 2006; 154: 461-6.
19. Yamanaka K, Clark R, Dowgiert R, et al. Expression of
interleukin-18 and caspase-1 in cutaneous T-cell
lymphoma. Clin Cancer Res 2006; 12: 376-82.
20. Koizumi H, Sato-Matsumura KC, Nakamura H, et al.
Distribution of IL-18 and IL-18 receptor in human skin:
various forms of IL-18 are produced in keratinocytes. Arch
Dermatol Res 2001; 293: 325-33 .
21. Chang C, Magracheva E, Kozlov S, et al. Crystal structure
of interleukin-19 defines subfamily of helical cytokines. 
J Biol Chem 2003; 278: 3308-13. 
22. Otkjaer K, Kragballe KV, Funding AT, et al. Interleukin 19
and interleukin-20 and their receptors in psoriasis. Br 
J Dermatol 2005; 153: 911-8.
23. Piskin G, Tursen U, Sylva-Steenl RMR, Bos JD, Teunissen
MBM. Clinical improvement in chronic plaque type psoriasis
lesion after narrow band UVB therapy is accompanied by
a decrease in the expression of IFN-γ inducers IL-12 IL-18
and IL-23. Exp Dermatol 2004; 13: 764-72.
24. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H.
Interleukin-18 regulates both Th1 and Th2 responses.
Annu Rev Immunol 2001; 19: 423-74.
25. Kong J, Grando SA, Li YC. Regulation of IL-1 family
cytokines IL-1α, IL-1 receptor antagonist, and IL-18 by 1,25-
dihydroxyvitamin D in primary keratinocytes. J Immunol
2006; 176: 3780-7.
26. Smeltz RB. Profound enhancement of IL-12/IL-18 pathway
of IFN-γ section in human CD8+ memory T cell subset via
IL-15. J Immunol 2007; 178: 4786-92.
27.  Tak PP, Bacchi M, Bertolino M, Desson A. Phar  -
macokinetics of IL-18 binding protein in healthy volunteers
and subjects with rheumatoid arthritis or plaque psoriasis.
Eur J Drug Metab Pharmacokinet 2006; 31: 109-16.
28. Trinquet QV, Fogel P, Aldana-Jammayrac O, et al.
Interleukin 19 gene expression profile in psoriasis: anaylsis
of impact of body site location and clinical severity. 
Br J Dermatol 2005; 152: 489-504. 
29. Craven NM, Jackson CW, Kirby B, et al. Cytokine gene
polymorphism in psoriasis. Br J Dermatol 2001; 144: 
849-53.
30. Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring
quality of life of patients with different clinical types of
psoriasis using the SF-36. Br J Dermatol 2006; 154: 
844-9.
31. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding
of severe acute respiratory syndrome associated corona
virus is associated with genetic polymorphism. Clin Infect
Dis 2006; 42: 1561-9. 
Hanaa Rasmy Mohamed Attia, Nancy Mikhael, Somaia Ismail
970 Arch Med Sci 6, December / 2010